ProShares UltraPro Short NASDAQ Biotechnology
ZBIO
ZBIO was delisted on the 27th of March, 2020.
7 hedge funds and large institutions have $1.67M invested in ProShares UltraPro Short NASDAQ Biotechnology in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and closing their positions.
86% more capital invested
Capital invested by funds: $896K → $1.67M (+$769K)
17% more funds holding
Funds holding: 6 → 7 (+1)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
69% less call options, than puts
Call options by funds: $149K | Put options by funds: $487K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$833K |
| 2 |
Jane Street
New York
|
+$378K |
| 3 |
Morgan Stanley
New York
|
+$14.4K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$9.87K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$78.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$12.5K |
| 3 |
CG
Cutler Group
San Francisco,
California
|
-$129 |
ZBIO Hedge Fund Activity: Q2 2017 in Review
7 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) for Q2 2017, worth a combined $1.67M — up 86% from $896K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ZBIO positions and 0 closed out — a net gain of 1 holder — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Virtu Financial, adding an estimated $833K. The largest seller was Susquehanna International Group, cutting an estimated $78.3K.
- 7 institutional investors held ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) as of Q2 2017, up from 6 in Q1 2017.
- Funds reported $1.67M of ProShares UltraPro Short NASDAQ Biotechnology stock for Q2 2017, up 86% quarter-over-quarter.
- 1 fund opened new ProShares UltraPro Short NASDAQ Biotechnology positions in Q2 2017 and 0 closed out, a net change of +1 holder.
- The largest ProShares UltraPro Short NASDAQ Biotechnology buyer in Q2 2017 was Virtu Financial, an estimated $833K added.
- The largest ProShares UltraPro Short NASDAQ Biotechnology seller in Q2 2017 was Susquehanna International Group, an estimated $78.3K sold.
Based on aggregated 13F filings for Q2 2017.